STOK

Stoke Therapeutics, Inc. (STOK) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Stoke Therapeutics is a late-stage clinical biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases. The company's lead asset, zorevunersen (STK-001), is in Phase 3 clinical trials for Dravet syndrome. A second candidate, STK-002, is in development for Autosomal Dominant Optic Atrophy (ADOA). The company operates as a single segment and is classified as a "smaller reporting company."

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: YTD revenue increased by $163.4 million compared to the prior year. This was driven primarily by the recognition of $150.8 million related to the IP license performance obligation and $4.9 million for global development activities under the new Biogen collaboration (effective Feb 2025). Additionally, $5.7 million was recognized in Q2 related to the discontinuation of two programs under the Acadia Pharmaceuticals agreement.
• Profitability Shift: The company reported a net income of $89.4 million for the six months ended June 30, 2025, compared to a net loss of $52.1 million in the same period in 2024. This turnaround is attributable to the large upfront revenue recognition from the Biogen deal, offset by a $1.3 million tax provision.
• Operating Expenses: R&D expenses increased by $15.0 million YTD, primarily due to increased costs for the zorevunersen program ($11.3 million increase) and personnel-related expenses ($5.8 million increase).
• Liquidity: Cash, cash equivalents, and marketable securities increased from $246.7 million at year-end 2024 to $355.0 million at June 30, 2025, bolstered by the Biogen upfront payment.

Guidance, Outlook, and Risks

• Clinical Progress: The Phase 3 EMPEROR study for zorevunersen in Dravet syndrome was initiated in May 2025, with the first patient dosed in August 2025. The Phase 1 OSPREY study for STK-002 (ADOA) is expected to enroll its first patient in the second half of 2025.
• Liquidity Outlook: Management believes current cash resources of approximately $355.0 million will fund operations through mid-2028.
• Collaboration Updates:
  • Biogen: Joint development of zorevunersen outside North America. Stoke receives 70% of development costs; Biogen receives 30%. Stoke retains rights in the U.S., Canada, and Mexico.
  • Acadia: In May 2025, Acadia elected to discontinue the MECP2 and undisclosed neurodevelopmental targets. The SYNGAP1 program remains active.
• Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. The company is assessing the impact, which includes the restoration of 100% bonus depreciation and immediate expensing of domestic R&D expenditures.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure additional capital if needed, reliance on third-party manufacturers, and potential regulatory delays. The company has a history of operating losses and expects to continue incurring losses until product commercialization.

Investor Verification Checklist

• Verify the specific terms and milestone payment schedules of the Biogen collaboration to understand future revenue potential beyond the upfront payment.
• Monitor enrollment rates and interim data readouts for the Phase 3 EMPEROR trial for zorevunersen, as this is the primary catalyst for commercialization.
• Review the impact of the Acadia program discontinuations on the company's pipeline depth and future royalty potential.
• Assess the company's burn rate relative to the mid-2028 liquidity runway to determine if future capital raises will be necessary.
• Confirm the status of the 2025 Shelf Registration Statement (effective July 11, 2025) to evaluate the company's ability to raise equity capital efficiently.